Increased circulating Lin-/lowCD33+HLA-DR- myeloid-derived suppressor cells in hepatocellular carcinoma patients

Hepatology Research

Volumn 44, Issue 6, 2014, Pages 639-650

  Shen, Peng ^a   Wang, Aijuan ^a   He, Mengye ^a   Wang, Qingqing ^a   Zheng, Shusen ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Cyclooxygenase; Hepatocellular carcinoma; Immunosuppression; Matrix metalloproteinase; Myeloid derived suppressor cells

Indexed keywords

CD33 ANTIGEN; COLLAGENASE 3; CYCLOOXYGENASE 2; GAMMA INTERFERON; HLA DR ANTIGEN; MONOCLONAL ANTIBODY; NITRIC OXIDE SYNTHASE; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BONE MARROW CELL; CANCER PATIENT; CELLULAR IMMUNITY; CHILD PUGH SCORE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; FLOW CYTOMETRY; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MYELOID DERIVED SUPPRESSOR CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPPRESSOR CELL; T LYMPHOCYTE SUBPOPULATION;

EID: 84885956598     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12167     Document Type: Article

References (52)

1. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007; 117: 1137-1146.
2. Gabrilovich DI, Velders M, Sotomayor E, Kast WM. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 2001; 166: 5398-5406.
3. Serafini P, De Santo C, Marigo I etal. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 2004; 53: 64-72.
4. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006; 16: 53-65.
5. Gallina G, Dolcetti L, SeraWni P etal. Tumors induce a subset of inXammatory monocytes with immunosuppressive activity on CD8 + T cells. J Clin Invest 2006; 116: 2777-2790.
6. Frey AB. Myeloid suppressor cells regulate the adaptive immune response to cancer. J Clin Invest 2006; 116: 2587-2590.
7. Zea AH, Rodriguez PC, Atkins MB etal. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005; 65: 3044-3048.
8. Schmielau J, Nalesnik MA, Finn OJ. Suppressed T-cell receptor zeta chain expression and cytokine production in pancreatic cancer patients. Clin Cancer Res 2001; 7 (3 Suppl): 933s-939.
9. Almand B, Clark JI, Nikitina E etal. Increased production of immature myeloid cells in cancer patients; A mechanism of immunosuppression in cancer. J Immunol 2001; 166: 678-689.
10. Pak AS, Wright MA, Matthews JP, Collins SL, Petruzzelli GJ, Young MR. Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin Cancer Res 1995; 1: 95-103.
11. Mirza N, Fishman M, Fricke I. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006; 66: 9299-9307.
12. Hoechst B, Ormandy LA, Ballmaier M etal. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008; 135: 234-243.
13. Liu CY, Wang YM, Wang CL etal. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14-/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol 2010; 136: 35-45.
14. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009; 58: 49-59.
15. Ribechini E, Greifenberg V, Sandwick S, Lutz MB. Subsets, expansion and activation of myeloid-derived suppressor cells. Med Microbiol Immunol 2010; 199: 273-281.
16. Rößner S, Voigtländer C, Wiethe C, Hänig J, Seifarth C, Lutz MB. Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro. Eur J Immunol 2005; 35: 3533-3544.
17. Bronte V, SeraWni P, Mazzoni A, Segal DM, Zanovello P. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol 2003; 24: 302-306.
18. Nagaraj S, Gupta K, Pisarev V etal. Altered recognition of antigen is a mechanism of CD8(+) T cell tolerance in cancer. Nat Med 2007; 13: 828-835.
19. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 2001; 61: 4756-4760.
20. Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol 2009; 182: 240-249.
21. Pan PY, Wang GX, Yin B etal. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 2008; 111: 219-228.
22. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007; 67: 4507-4513.
23. Gabrilovich D, Ishida T, Oyama T etal. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietie lineages in vivo. Blood 1998; 92: 4150-4166.
24. Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 2005; 174: 636-645.
25. Hida T, Yatabe Y, Achiwa H etal. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998; 58: 3761-3764.
26. Riedl K, Krysan K, Pold M etal. Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist Updat 2004; 7: 169-184.
27. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003; 4: 431-436.
28. Yue X, Yang F, Yang Y etal. Induction of cyclooxygenase-2 expression by hepatitis B virus depends on demethylation-associated recruitment of transcription factors to the promoter. Virology 2011; 8: 118-133.
29. Jeong SW, Jang JY, Lee SH etal. Increased expression of cyclooxygenase-2 is associated with the progression to cirrhosis. Korean J Intern Med 2010; 25: 364-371.
30. Gao YW, Chen YX, Wang ZM etal. Increased expression of cyclooxygenase-2 and increased infiltration of regulatory T cells in tumors of patients with hepatocellular carcinoma. Digestion 2009; 79: 169-176.
31. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005; 80: S254-264.
32. Shankaran V, Ikeda H, Bruce AT etal. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-1111.
33. Street SE, Trapani JA, MacGregor D, Smyth MJ. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 2002; 196: 129-134.
34. Rosenberg SA, Sherry RM, Morton KE etal. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005; 175: 6169-6176.
35. Radoja S, Saio M, Schaer D, Koneru M, Vukmanovic S, Frey AB. CD8(+) tumor-infiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis. J Immunol 2001; 167: 5042-5051.
36. Pittet MJ, Zippelius A, Speiser DE etal. Ex vivo IFN-gama secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases. J Immunol 2001; 166: 7634-7640.
37. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A 2004; 101: 14639-14645.
38. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 2006; 8: 1369-1375.
39. Yang L, Huang J, Ren X etal. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008; 13: 23-35.
40. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 2008; 118: 3367-3377.
41. DeNardo DG, Barreto JB, Andreu P etal. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009; 16: 91-102.
42. Belotti D, Paganoni P, Manenti L etal. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 2003; 63: 5224-5229.
43. Dean RA, Butler GS, Hamma-Kourbali Y etal. Identification of candidate angiogenic inhibitors processed by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic screens: disruption of vascular endothelial growth factor (VEGF)/heparin affin regulatory peptide (pleiotrophin) and VEGF/Connective tissue growth factor angiogenic inhibitory complexes by MMP-2 proteolysis. Mol Cell Biol 2007; 27: 8454-8465.
44. Du R, Lu KV, Petritsch C etal. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008; 13: 206-220.
45. Mauviel A. Cytokine regulation of metalloproteinase gene expression. J Cell Biochem 1993; 53: 288-295.
46. Freije JM, Díez-Itza I, Balbín M etal. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 1994; 269: 16766-16773.
47. Johansson N, Airola K, Grenman R, Kariniemi AL, Saarialho-Kere U, Kahari VM. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am J Pathol 1997; 151: 499-508.
48. Cazorla M, Hernández L, Nadal A etal. Collagenase-3 expression is associated with advanced local invasion in human squamous cell carcinomas of the larynx. J Pathol 1998; 186: 144-150.
49. Hsu CP, Shen GH, Ko JL. Matrix metalloproteinase-13 expression is associated with bone marrow microinvolvement and prognosis in non-small cell lung cancer. Lung Cancer 2006; 52: 349-357.
50. Nikkola J, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kähäri VM, Pyrhönen S. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res 2005; 11: 5158-5166.
51. Qin L, Han Y-P. Epigenetic repression of matrix metalloproteinases in myofibroblastic hepatic stellate cells through histone deacetylases 4. Am J Pathol 2010; 177: 1915-1928.
52. Lee CF, Ling ZQ, Zhao T etal. Genomic-wide analysis of lymphatic metastasis-associated genes in human hepatocellular carcinoma. World J Gastroenterol 2009; 15: 356-365.